1st May 2007 17:10
Skyepharma PLC01 May 2007 FOR IMMEDIATE RELEASE Addendum to results announcement SkyePharma PLC (LSE:SKP; NASDAQ: SKYE), LONDON, ENGLAND, 1 May 2007 This announcement is to correct a minor typographical error on the resultsannouncement of 26 April 2007. Whilst the total figures for earnings per share for 2006 were correctly statedin the original announcement, the split between pre-exceptional and exceptionalearnings per share for 2006 was incorrectly stated on the face of the profit andloss account. The figures were correctly stated in Note 6 to the originalannouncement, an extract of which is set out below: Earnings per share Year to Year to 31 December 2006 31 December 2005 (restated) Continuing operationsLoss per Ordinary Share before exceptional items (3.4)p (2.5)pExceptional items 0.9p (0.8)p _____ _____Basic and diluted loss per Ordinary Share (2.5)p (3.3)p _____ _____ Continuing and discontinued operationsLoss per Ordinary Share before exceptional items (6.4)p (4.7)pExceptional items (4.0)p (3.4)p _____ _____Basic and diluted loss per Ordinary Share (10.4)p (8.1)p _____ _____ For further information please contact: SkyePharma PLC Frank Condella, Chief Executive Officer Ken Cunningham, Chief Operating Officer +44 207 491 1777 Peter Grant, Finance Director Financial Dynamics (London enquiries) David Yates / Deborah Scott +44 207 831 3113 Trout Group (US enquiries) Christine Labaree / Seth Lewis +1 617 583 1308 About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops newformulations of known molecules to provide a clinical advantage and life-cycleextension. The Group has ten approved products in the areas of oral, inhalationand topical delivery. The Group's products are marketed throughout the world byleading pharmaceutical companies. For more information, visitwww.skyepharma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L